ONC-392,Pembrolizumab
biontech,Merck
['lung', 'solid tumor', 'biontech']
biontech and oncoc4 reported phase 1/2 data in non-small cell lung cancer for an immunotherapy called gotistobart. earlier this year, the german company inked a deal to share in the development of the drug in various types of solid tumors. 
Tracking what's next in medical innovation from hospitals, payers, medtech, pharma, digital & beyond. A @breakingmedia site.